Interpace Biosciences, Inc. (IDXGD)
OTCMKTS · Delayed Price · Currency is USD
6.91
+0.40 (6.18%)
At close: Sep 4, 2026
Interpace Biosciences Employees
Interpace Biosciences had 102 employees as of December 31, 2025. The number of employees decreased by 9 or -8.11% compared to the previous year.
Employees
102
Change (1Y)
-9
Growth (1Y)
-8.11%
Revenue / Employee
$354,353
Profits / Employee
$239,676
Market Cap
38.30M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 102 | -9 | -8.11% | 102 | 0 |
| Dec 31, 2024 | 111 | 3 | 2.78% | 111 | 0 |
| Dec 31, 2023 | 108 | 14 | 14.89% | 108 | 0 |
| Dec 31, 2022 | 94 | -53 | -36.05% | 94 | 0 |
| Dec 31, 2021 | 147 | -5 | -3.29% | 147 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Interpace Biosciences News
- 9 days ago - Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting - GlobeNewsWire
- 3 months ago - Interpace Biosciences Announces First Quarter 2026 Financial and Business Results - GlobeNewsWire
- 5 months ago - Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results - GlobeNewsWire
- 5 months ago - Interpace Biosciences Earnings release: Q4 2025 - Filings
- 9 months ago - Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners - GlobeNewsWire
- 9 months ago - Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results - GlobeNewsWire
- 11 months ago - Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - GlobeNewsWire
- 1 year ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire